The global Viral Vector Manufacturing CDMO Services market size is predicted to grow from US$ 5458 million in 2024 to US$ 9420 million in 2030; it is expected to grow at a CAGR of 9.5% from 2024 to 2030.

Viral Vector Manufacturing CDMO services refer to providing professional viral vector production and development services to biopharmaceutical companies. These viral vectors are usually used in gene therapy, vaccine development, cell therapy and other fields. CDMO organizations are responsible for the design and optimization of viral vectors to large-scale production in accordance with GMP standards, ensuring the safety and effectiveness of the products, while strictly controlling the quality of each production link. These services provide key technical support for biopharmaceutical companies to help accelerate the development and commercialization of their products.

United States market for Viral Vector Manufacturing CDMO Services is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Viral Vector Manufacturing CDMO Services is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Viral Vector Manufacturing CDMO Services is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Viral Vector Manufacturing CDMO Services players cover Thermo Fisher Scientific Inc., Revvity, Charles River Laboratories, AGC Inc. Group (AGC Biologics), NorthX Biologics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

LPI (LP Information) newest research report, the Viral Vector Manufacturing CDMO Services Industry Forecast looks at past sales and reviews total world Viral Vector Manufacturing CDMO Services sales in 2023, providing a comprehensive analysis by region and market sector of projected Viral Vector Manufacturing CDMO Services sales for 2024 through 2030. With Viral Vector Manufacturing CDMO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector Manufacturing CDMO Services industry.

This Insight Report provides a comprehensive analysis of the global Viral Vector Manufacturing CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Viral Vector Manufacturing CDMO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Viral Vector Manufacturing CDMO Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector Manufacturing CDMO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector Manufacturing CDMO Services.

This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector Manufacturing CDMO Services market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Adeno-associated Virus
    Lentivirus
    Retrovirus
    Adenovirus
    Other

Segmentation by Application:

    Gene Therapy
    Vaccine Development
    Cell Therapy

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    Thermo Fisher Scientific Inc.
    Revvity
    Charles River Laboratories
    AGC Inc. Group (AGC Biologics)
    NorthX Biologics
    Lonza
    Avid Bioservices, Inc.
    Exothera
    Merck KGaA
    Batavia Biosciences
    SK pharmteco Inc.
    Biovian
    Curia Vector Technology
    Esco Aster
    ABL, Inc.
    Genezen
    Pharmaron
    Roche AG
    FinVector
    FUJIFILM Diosynth Biotechnologies
    Kaneka Eurogentec S.A. (Kaneka Corporation)
    Oxford Biomedica plc
    Sanofi S.A.